 |
|
Scientists Show Drug Can Counteract Muscular Dystrophy in Mice
October 05, 2006Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other institutions have demonstrated for the first time that a single drug can rebuild damaged muscle in two strains of mice that develop diseases comparable to two human forms of muscular dystrophy. This advance, which is reported online in Nature Medicine, is the latest from a research collaboration that began several years ago by the teams of Vittorio Sartorelli, M.D., at NIAMS and Pier Lorenzo Puri, M.D., Ph.D., now at Dulbecco Telethon Institute (DTI) in Rome, Italy and The Burnham Institute in La Jolla, Calif.
The scientists tested trichostatin A (TSA), an inhibitor of the enzyme deacetylase, in two mouse models of muscular dystrophy (MD): one that naturally develops a disease similar to Duchenne muscular dystrophy in humans, the other genetically altered to develop a form of dystrophy similar to the human limb-girdle muscular dystrophy. At 45 to 90 days of age, the muscles of the MD mice showed much fibrous tissue and infiltration of inflammatory cells. Unlike healthy mice, the mice with MD were unable to either run on a treadmill or swim. MD mice given TSA daily for two to three months, however, were virtually indistinguishable from healthy mice, and biophysical studies showed virtually no difference between the muscle strength of the mice with MD given the deacetylase inhibitor and healthy mice.
"This is the first example of using a drug to counteract muscular dystrophy in mouse models," says Dr. Sartorelli. Yet he points out that the drug is only promoting muscle regeneration - it is not curing the defect that causes muscle deterioration. Further studies are needed to determine how long the drug works and if it works in larger animals with bigger muscles, such as dogs, before such drugs can be tested in people.
The finding has its roots in several of the group's earlier advances, the first of which was reported in 2002 in the Proceedings of the National Academy of Sciences 1. The scientists found that treating muscle cells with deacetylase inhibitors caused the cells to grow larger and differentiate better, says Dr. Sartorelli, the group leader of the Muscle Gene Expression Group in NIAMS' Laboratory of Muscle Biology. The next advance, published two years later in the journal Developmental Cell 2, was the discovery that the inhibitor worked by changing gene expression, causing some genes to be upregulated, or make more protein, and others to be downregulated, or make less protein. Among the genes positively regulated by the inhibitors was a gene for a key protein called follistatin.
"It was known that follistatin had a role in muscle development, so by understanding normal muscle development we knew that follistatin would block the activity of another protein called myostatin," says Dr. Sartorelli. "If you block myostatin, you get big muscles."
One way of inactivating myostatin is to upregulate follistatin. Basically, what follistatin does is to prevent myostatin from working, says Dr. Sartorelli. When his group treated the cells with deacetylase inhibitors, they saw that the cells became large and that follistatin was overexpressed. However, when the group treated the cells with the inhibitors and then used other agents to block follistatin, the cells didn't become bigger, showing that one of the most important pathways the inhibitors use to create bigger muscles involves the activation of follistatin. "If you didn't have follistatin anymore, these drugs didn't work," he says.
Moreover, Drs. Sartorelli's and Puri's groups were able to show that in normal animals, follistatin is upregulated when muscle is damaged. When the researchers induced muscle damage and then gave the inhibitors, follistatin was even more expressed, as were two proteins that reflect increased muscle regeneration.
Other Italian groups contributed to the present study, including the Istituto Dermatologico dell' Immacolata of Rome; the Department of Experimental Medicine, Human Physiology Unit, University of Pavia; and the Laboratory of Vascular Biology and Genetic Therapy, Centro Cardiologico Monzino, Milan.
This study was supported in part by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health. Other support was provided by Telethon (Italy), the Muscular Dystrophy Association and the Parent Project Organization (Italy).
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the Department of Health and Human Services' National Institutes of Health, is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For more information about NIAMS, call the information Clearinghouse at (301) 495-4484 or (877) 22-NIAMS (free call) or visit the NIAMS Web site at www.niams.nih.gov.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The National Institutes of Health (NIH)
The finding has its roots in several of the group's earlier advances, the first of which was reported in 2002 in the Proceedings of the National Academy of Sciences 1. The scientists found that treating muscle cells with deacetylase inhibitors caused the cells to grow larger and differentiate better, says Dr. Sartorelli, the group leader of the Muscle Gene Expression Group in NIAMS' Laboratory of Muscle Biology. The next advance, published two years later in the journal Developmental Cell 2, was the discovery that the inhibitor worked by changing gene expression, causing some genes to be upregulated, or make more protein, and others to be downregulated, or make less protein. Among the genes positively regulated by the inhibitors was a gene for a key protein called follistatin.
"It was known that follistatin had a role in muscle development, so by understanding normal muscle development we knew that follistatin would block the activity of another protein called myostatin," says Dr. Sartorelli. "If you block myostatin, you get big muscles."
One way of inactivating myostatin is to upregulate follistatin. Basically, what follistatin does is to prevent myostatin from working, says Dr. Sartorelli. When his group treated the cells with deacetylase inhibitors, they saw that the cells became large and that follistatin was overexpressed. However, when the group treated the cells with the inhibitors and then used other agents to block follistatin, the cells didn't become bigger, showing that one of the most important pathways the inhibitors use to create bigger muscles involves the activation of follistatin. "If you didn't have follistatin anymore, these drugs didn't work," he says.
Moreover, Drs. Sartorelli's and Puri's groups were able to show that in normal animals, follistatin is upregulated when muscle is damaged. When the researchers induced muscle damage and then gave the inhibitors, follistatin was even more expressed, as were two proteins that reflect increased muscle regeneration.
Other Italian groups contributed to the present study, including the Istituto Dermatologico dell' Immacolata of Rome; the Department of Experimental Medicine, Human Physiology Unit, University of Pavia; and the Laboratory of Vascular Biology and Genetic Therapy, Centro Cardiologico Monzino, Milan.
This study was supported in part by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health. Other support was provided by Telethon (Italy), the Muscular Dystrophy Association and the Parent Project Organization (Italy).
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the Department of Health and Human Services' National Institutes of Health, is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For more information about NIAMS, call the information Clearinghouse at (301) 495-4484 or (877) 22-NIAMS (free call) or visit the NIAMS Web site at www.niams.nih.gov.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The National Institutes of Health (NIH)
Muscular Dystrophy Current Events and Muscular Dystrophy News RSSExon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
To regenerate muscle, cellular garbage men must become builders
For scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, what seemed like a disappointing result turned out to be an important discovery.
Zoo volunteers help explain mysteries of the genome
As the University of Leicester approaches the 25th anniversary of the discovery of DNA fingerprinting (September 10), Leicester geneticists interested in a particular type of DNA are receiving some help from an unusual band of assistants.
Small molecule inhibits pathology associated with myotonic dystrophy type 1
Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.
Researchers identify new function for protein missing in Duchenne muscular dystrophy
Researchers at the University of Minnesota and National Institutes of Health have identified a new function for the protein missing in people with the most common and ultimately lethal form of childhood muscular dystrophy.
Sticky protein helps reinforce fragile muscle membranes
A new study by scientists at the University of Iowa shows why muscle membranes don't rupture when healthy people exercise.
Stem cell surprise for tissue regeneration
Scientists working at the Carnegie Institution's Department of Embryology, with colleagues, have overturned previous research that identified critical genes for making muscle stem cells.
Researchers make progress toward early identification of muscular dystrophy
The saying "Knowing is half the battle" is never more true than when discussing early treatment of disease. Muscular dystrophy is one such disease where patients can benefit from early treatment. Now, new research is moving doctors and scientists closer to disease diagnosis in advance of patient symptoms.
Jumping genes discovery 'challenges current assumptions'
Jumping genes do most of their jumping, not during the development of sperm and egg cells, but during the development of the embryo itself.
New therapy substitutes missing protein in those with muscular dystrophy
Researchers at the University of Minnesota Medical School have discovered a new therapy that shows potential to treat people with Duchenne muscular dystrophy, a fatal disease and the most common form of muscular dystrophy in children.
More Muscular Dystrophy Current Events and Muscular Dystrophy News Articles
 |
Muscular Dystrophy (The Facts) by Alan E.H. Emery (Author) The muscular dystrophies are a group of genetic diseases that severely affect children and adults. For sufferers and their family, the illness presents enormous physical and psychological challenges. Written specifically for people with muscular dystrophy and their families, this book answers many of the questions asked about how and why muscular dystrophy occurs, and how it will affect the life of a recently diagnosed child. As well as presenting the reader with advice and an explanation of muscular dystrophy, the book also guides the reader towards further information on societies and support groups around the world, and reliable internet resources. It also contains a full glossary to aid the reader in their understanding of the disease. The different types of... |
 |
Muscular Dystrophy in Children: A Guide for Families by Irwin M. Siegel (Author) Written for children with muscular dystrophy (MD) and their families, friends and teachers, this book is a guide through the often-frightening labyrinth of medical care that follows the diagnosis of MD. Forthright, clear, supportive and empowering, the book helps readers understand the significance of the signs and symptoms of the disease, treatment options, the disease's probable course and what may affect it, and choices in directing therapy. This incomparable guide covers: * The diagnosis of childhood muscular dystrophy Early childhood Prepuberty Fractures Adolescence Late problems Caregiver's self-help guide New research Suggestions for further reading. |
 |
Muscular Dystrophy (Diseases and Disorders) by Melissa Abramovitz (Author) |
 |
Duchenne Muscular Dystrophy: Advances in Therapeutics (Neurological Disease and Therapy) by Jeffrey S. Chamberlain (Editor), Thomas A. Rando (Editor) Duchenne Muscular Dystrophy (DMD) is one of the most prevalent genetic disorders of childhood and currently stands as an incurable condition. This authoritative guide provides a clear overview of the latest current and experimental approaches to the treatment of DMD and examines the clinical, genetic, and pathophysiological aspects of the disease in the context of emerging therapeutic modalities. The only available source on the subject, this reference emphasizes the importance of accurate diagnosis, carrier detection, and genetic counseling, and supplies state-of-the-art contributions on pharmacological interventions, regenerative medicine, and gene therapy. |
 |
Muscular Dystrophy: theFacts by Alan Emery (Author) European Neuromuscular Centre, Baarn, The Netherlands. Discusses living with muscular dystrophy and coping with its physical effects. Written for people with this illness and their families, it answers many questions asked by those diagnosed with muscular dystrophy. Previous edition: c1994. Softcover. |
 |
The Muscular Dystrophies by Alan E. H. Emery (Editor) The muscular dystrophies are an important group of inherited disorders. They are characterized by muscle wasting and weakness, but vary considerably in their clinical manifestations and severity. This text reviews our understanding of the most important of these disorders. In many instances, the genes and protein products responsible for the dystrophies have been identified and it is now possible to establish a precise diagnosis, detect preclinical cases, identify carriers and offer prenatal dianostic testing. The book goes on to describe the opportunities for management of the symptoms through respiratory care, physiotherapy and surgical correction of contracture, and examines the potential, in the future, for effective treatment utilizing the new techniques of gene and cell therapy.... |
 |
Moonrise: One Family, Genetic Identity, and Muscular Dystrophy by Penny Wolfson (Author) In this riveting and thought-provoking memoir about her family, her son Ansel, and his progressive disability, Penny Wolfson embarks on a quest that explores special education, giftedness, prenatal testing, and the genes she shares with her mother, sisters, and son. While Moonrise is an eloquent narrative of one family, it also asks profound questions about our genetic selves. |
 |
My Buddy (An Owlet Book) by Audrey Osofsky (Author), Ted Rand (Illustrator) Buddy is the best dog a boy could have. He and his master are always together. They play ball, and go for walks, and take good care of each other. Nothing can separate them. They're a team. |
 |
Muscular Dystrophy (Genetic and Developmental Diseases and Disorders) by Paula Johanson (Author) |
|
39 Pounds of Love Starring: Ami Ankilewitz Directed By: Dani Menkin Also With: Chris Gubisch (Composer), Paul Petschek (Editor), Sam Bauer (Editor), Geoffrey O'Brien (Editor), Pablo Petschek (Editor) |
| © 2009 BrightSurf.com |